Dydroton25 mg

Dydroton is a thiazide-like diuretic used mainly to lower blood pressure and reduce fluid retention.

Established / FDA-approved uses

• Hypertension: Dydroton is indicated for the management of high blood pressure, either alone or in combination with other antihypertensive agents.
• Edema: Dydroton is indicated for the management of edema associated with congestive heart failure, hepatic cirrhosis, corticosteroid and estrogen therapy, and various forms of renal dysfunction (including nephrotic syndrome and acute glomerulonephritis).

Guideline-supported / commonly used off-label

• Prevention of recurrent calcium-containing kidney stones in patients with hypercalciuria (reduces urinary calcium excretion).
• Adjunct in nephrogenic diabetes insipidus, where it paradoxically reduces urine volume (used off-label, sometimes combined with amiloride).

Use for any indication other than hypertension or edema should be guided by a physician's assessment, as these are not primary approved indications.

Each tablet contains Chlorthalidone as the active ingredient, commonly available in strengths such as 6.25 mg, 12.5 mg, 25 mg, and 50 mg, along with standard pharmaceutical excipients.

Dydroton is a monosulfonamide, phthalimidine-derivative diuretic classified as "thiazide-like" because it shares the mechanism of action of the thiazide diuretics, although it is not chemically a benzothiadiazine. It has a longer duration of action than many thiazides and has been extensively studied in major hypertension outcome trials.

Dydroton works by reducing sodium and water reabsorption in the kidney, which lowers blood volume and, with long-term use, reduces peripheral vascular resistance, resulting in lower blood pressure and reduced edema.

Thiazide-like diuretic (sulfonamide-derivative, phthalimidine class); antihypertensive agent. Dydroton belongs to this class.

Mechanism of action

Chlorthalidone inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, blocking reabsorption of sodium and chloride. This increases urinary excretion of sodium, chloride, and water, and also increases excretion of potassium and magnesium while promoting calcium reabsorption.

Pharmacokinetics

• Onset of action: within 2–3 hours
• Duration of action: approximately 24–72 hours (notably longer than hydrochlorothiazide)
• Protein binding: highly bound to erythrocytes and plasma proteins, giving it a long elimination half-life (approximately 40–60 hours)
• Elimination: primarily excreted unchanged in the urine

With chronic use, Chlorthalidone also produces a mild vasodilatory effect that contributes to sustained blood pressure lowering beyond its diuretic action.

• Take Dydroton by mouth, with or without food.
• Take the dose in the morning to reduce the need to urinate during the night.
• Swallow the tablet with a glass of water; do not crush unless advised by your physician.
• Try to take Dydroton at the same time each day for consistent effect.
• If a dose is missed, take it as soon as remembered unless it is close to the next dose; do not double the dose.
• Do not stop Dydroton suddenly without consulting your physician, especially if being used for blood pressure control.

• Lithium: Dydroton reduces renal clearance of lithium, increasing the risk of lithium toxicity; concurrent use is generally avoided or requires close lithium level monitoring.
• NSAIDs (e.g., ibuprofen, indomethacin): may reduce the diuretic and antihypertensive effect of Dydroton and increase the risk of renal impairment, particularly in dehydrated or elderly patients.
• Digoxin: Dydroton-induced hypokalemia or hypomagnesemia can increase the risk of digoxin toxicity and cardiac arrhythmias.
• Other antihypertensives and diuretics: additive blood-pressure-lowering and electrolyte effects; dose adjustment may be needed.
• Corticosteroids and ACTH: may worsen Dydroton-induced hypokalemia.
• Antidiabetic agents (insulin, oral hypoglycemics): Dydroton can raise blood glucose, potentially reducing glycemic control and requiring dose adjustment.
• Cholestyramine/colestipol: may reduce absorption of Dydroton; separate dosing times.
• Other drugs that prolong the QT interval or are affected by hypokalemia: Dydroton-induced electrolyte changes may increase arrhythmia risk when combined with such drugs.

Common

• Dizziness or lightheadedness
• Electrolyte disturbances (low potassium, low sodium, low magnesium)
• Elevated uric acid levels
• Increased blood glucose
• Increased sensitivity to sunlight (photosensitivity)
• Gastrointestinal upset (nausea, loss of appetite)
• Muscle cramps

Less common / serious

• Severe electrolyte imbalance leading to weakness, confusion, or irregular heartbeat
• Hypersensitivity reactions (skin rash, and rarely more severe reactions)
• Acute pancreatitis (rare)
• Blood cell count abnormalities (rare)
• Acute myopia and secondary angle-closure glaucoma (rare, class effect of thiazide-type diuretics)

Seek prompt medical attention for signs of severe electrolyte imbalance, allergic reaction, or sudden vision changes/eye pain.

Pregnancy: Dydroton should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus. Thiazide-type diuretics used near term have been associated with neonatal jaundice and thrombocytopenia in isolated reports. Dydroton is not recommended for routine treatment of pregnancy-related edema or hypertension without physician guidance.

Lactation: Dydroton is excreted into breast milk in small amounts and may suppress lactation. Use during breastfeeding only under medical supervision, weighing benefits against potential effects on the infant and milk supply.

Always consult a physician before starting or continuing Dydroton during pregnancy or breastfeeding.

• Electrolyte disturbances: Dydroton can cause hypokalemia, hyponatremia, and hypomagnesemia, particularly in elderly patients, those on other diuretics, or with poor oral intake. Periodic monitoring of electrolytes is recommended.
• Hyperuricemia/gout: Dydroton can raise uric acid levels and may precipitate an acute gout attack in susceptible patients.
• Hyperglycemia: Dydroton may unmask latent diabetes or worsen glycemic control in existing diabetics; monitor blood glucose.
• Hypercalcemia: Dydroton reduces urinary calcium excretion and may unmask hyperparathyroidism; use caution in patients with pre-existing hypercalcemia.
• Renal impairment: effectiveness is reduced at very low kidney function; monitor renal function during treatment.
• Hepatic impairment: use with caution, as fluid and electrolyte shifts can precipitate hepatic coma in patients with liver disease.
• Photosensitivity: photosensitivity reactions have been reported; minimize sun exposure and use sun protection.
• Sulfonamide cross-sensitivity: Dydroton is a sulfonamide derivative; a history of sulfonamide antibiotic allergy warrants caution, though true cross-reactivity with antibiotic sulfonamides is debated and considered low.
• Systemic lupus erythematosus: thiazide-type diuretics have been reported to cause exacerbation or activation of lupus erythematosus.
• Eye effects: rare reports of acute myopia and secondary angle-closure glaucoma; seek immediate care for sudden eye pain or vision changes.

Overdose of Dydroton may cause excessive diuresis leading to dehydration, electrolyte depletion (particularly potassium and sodium), low blood pressure, dizziness, weakness, and cardiac rhythm disturbances.

If overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Management is supportive and should be carried out by medical professionals, including monitoring and correction of fluid and electrolyte status; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Elderly: more susceptible to electrolyte disturbances and hypotension with Dydroton; use lower initial doses and monitor closely.
• Renal impairment: Dydroton is contraindicated in anuria; efficacy is reduced in significant renal impairment, and monitoring is required (see Contraindications and Precautions).
• Hepatic impairment: use with caution due to risk of hepatic coma from fluid/electrolyte shifts.
• Diabetics: Dydroton may worsen blood glucose control; monitor glucose levels.
• Gout patients: Dydroton may precipitate acute gout attacks due to elevated uric acid.
• Pediatric patients: safety and efficacy not well established; use only under specialist supervision if considered necessary.

For hypertension, Dydroton is typically used long-term as part of chronic blood pressure management, with regular physician follow-up and periodic laboratory monitoring. For edema, duration depends on the underlying condition and response, and treatment is guided and periodically reassessed by the prescribing physician. Dydroton should not be stopped or continued beyond the prescribed period without medical advice.

Diuretics > Thiazide-like diuretics (sulfonamide/phthalimidine derivatives). Chlorthalidone is a member of this class.

Chlorthalidone blocks the sodium-chloride cotransporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting excretion of sodium, chloride, and water. This lowers blood volume acutely and, with chronic use, is thought to also reduce peripheral vascular resistance, producing a sustained antihypertensive effect.

B (FDA legacy pregnancy category; use only if clearly needed, particularly near term — see Pregnancy and Lactation)

The safety and efficacy of Dydroton have not been well established in pediatric patients. Use in children, when considered necessary by a specialist, requires individualized, weight-based dosing and close monitoring of electrolytes, renal function, and growth. Dydroton is not routinely recommended for pediatric use outside specialist supervision.